Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Hannah M Hicks"'
Publikováno v:
Cancer Biology & Therapy, Vol 25, Iss 1 (2024)
ABSTRACTThyroid cancer is one of the deadliest endocrine cancers, and its incidence has been increasing. While mutations in BRAF are common in thyroid cancer, advanced PTC patients currently lack therapeutic options targeting the MAPK pathway, and de
Externí odkaz:
https://doaj.org/article/bf71560a73dc416187643a132237b04a
Autor:
Lays M. Sobral, Hannah M. Hicks, Janet K. Parrish, Tyler S. McCann, Joseph Hsieh, Andrew Goodspeed, James C. Costello, Joshua C. Black, Paul Jedlicka
Publikováno v:
Molecular Oncology, Vol 14, Iss 10, Pp 2471-2486 (2020)
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and young adults. RMS exists as two major disease subtypes, oncofusion‐negative RMS (FN‐RMS) and oncofusion‐positive RMS (FP‐RMS). FP‐RMS is characterized by recurren
Externí odkaz:
https://doaj.org/article/220840bd9fd744769639420b420d91fe
Autor:
Hannah M. Hicks, Nikita Pozdeyev, Sharon B. Sams, Umarani Pugazhenthi, Elise S. Bales, Marie-Claude Hofmann, Logan R. McKenna, Rebecca E. Schweppe
Publikováno v:
Molecular Cancer Research.
Mutations in BRAF are common in advanced papillary and anaplastic thyroid cancer (PTC and ATC). However, BRAF-mutant PTC patients currently lack therapies targeting this pathway. Despite the approved combination of BRAF and MEK1/2 inhibition for pati
Autor:
Sharon Sams, Laura A. Pike, Veronica L Espinoza, Christopher D. Raeburn, Philip Reigan, Rebecca E. Schweppe, Daniel V. LaBarbera, Nikita Pozdeyev, Hannah M Hicks, Logan R McKenna
Publikováno v:
Molecular Carcinogenesis. 60:201-212
Mutations in the BRAF gene are highly prevalent in thyroid cancer. However, the response rate of thyroid tumors to BRAF-directed therapies has been mixed. Increasingly, combination therapies inhibiting the MAPK pathway at multiple nodes have shown pr
Autor:
Tyler S. McCann, Joseph Hsieh, James C. Costello, Paul Jedlicka, Andrew Goodspeed, Lays M. Sobral, Janet K. Parrish, Hannah M. Hicks, Joshua C. Black
Publikováno v:
Molecular Oncology, Vol 14, Iss 10, Pp 2471-2486 (2020)
Molecular Oncology
Molecular Oncology
Fusion‐positive rhabdomyosarcoma (FP‐RMS) is an aggressive pediatric cancer. The chromatin factor KDM3A and the downstream transcription factor Ets1 comprise a new epigenetic axis that works together with, as well as independently of, the driver
Publikováno v:
Cancer Research. 82:2434-2434
Advanced papillary thyroid cancer (PTC) and anaplastic thyroid cancer (ATC) are the leading causes of endocrine cancer death. Mutations in the MAP kinase (MAPK) pathway are common in PTC and ATC, especially in BRAF, with a prevalence of 40-60%. Despi
Autor:
Hannah M Hicks, Deviyani M. Rao, Madeleine T Shackleford, Evelyn K. Bordeaux, Steffi Oesterreich, Matthew J. Sikora
Invasive lobular carcinoma of the breast (ILC) is strongly estrogen-driven and represents a unique context for estrogen receptor (ER) signaling. In ILC, ER controls the expression of the Wnt ligand WNT4, which is critical for endocrine response and a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::260346953725537a3c1ec9009a7ee06f
https://doi.org/10.1101/684530
https://doi.org/10.1101/684530
Publikováno v:
The American Biology Teacher. 77:676-680
Invasive species are an issue of global concern because they can have large impacts on ecosystems and are challenging to manage. We present an activity aimed at improving undergraduate students’ understanding of the ecological impacts and managemen
Autor:
Hannah M. Hicks
Publikováno v:
Public Integrity. 18:227-228
In today’s world, integrity appears to be based on the media value of a person’s successes and achievements. Such a valuation is shallow, morally unsatisfactory, and does not offer an optimistic ou...
Autor:
Hannah M. Hicks
Publikováno v:
Public Integrity. 17:409-410
Everybody lies, whether we realize it or not, and if you deny it, then you’re lying to yourself. Lying is innate, affecting nearly every decision we make and even those that we haven’t made yet. Ou...